Table 3.
Impact of comorbidities on the mortality of patients with COPD.
| Characteristics of the Study Population | COPD-COVID-19 Survivors (1 January–10 May 2020) |
COPD-COVID-19 Deceased (1 January–10 May 2020) |
OR (95% CI) p-Value |
|---|---|---|---|
| N | 719 | 74 | |
| Age | |||
| Years (mean ± SD) | 74 ± 11 | 77 ± 11 | 0.03 |
| Sex | |||
| Female (%) | 18 | 16 | 1.58 (0.37–3.25) |
| Comorbidities | |||
| Ischemic Heart disease (%) | 24 | 16 | 1.59 (0.84–3.02) |
| Heart failure (%) | 33 | 45 | 0.61 (0.37–0.99) |
| Arrythmia (%) | 18 | 22 | 0.81 (0.45–1.45) |
| Diabetes mellitus (%) | 41 | 41 | 1.00 (0.62–1.63) |
| Arterial Hypertension (%) | 76 | 77 | 0.96 (0.55–1.70) |
| Dyslipidemia (%) | 20 | 23 | 0.83 (0.47–1.47) |
| Pulmonary embolism (%) | 5 | 5 | 0.95 (0.39–1.46) |
| Stroke (%) | 11 | 16 | 0.76 (0.58–1.71) |
| Sleep Apnea (%) | 11 | 11 | 1.06 (0.49–2.29) |
| Smoking (%) | 34 | 28 | 1.33 (0.78–2.25) |